Atlas Trials

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Clinical trial NCT07377643 · RECRUITING

Trial details

NCT number
NCT07377643
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2026-02-10
Primary completion
2028-04-28
Enrollment
540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.